Funding Opportunities

submenu

Extramural grant review opportunity available

Writing a grant? Need another set of eyes?

The Masonic Cancer Center Science Council can appoint individuals to review cancer center faculty members' grant drafts* or grant ideas in a face-to-face setting or in writing, depending on the stage of grant development. The goal is to improve upon members' success in obtaining grants funded by the NCI, ACS, and other national cancer research organizations.

To request a review, contact Elizabeth Fedie, efedie@umn.edu, 624-0653.

*Members should submit their ideas or abstracts and specific aims one cycle (~3-4 months minimum) before the grant is due. We will usually provide feedback within 1 week.

News and notices

New Topic Areas for FY16: Bladder Cancer, Lymphoma, Pediatric Brain Tumors and Immunotherapy

The FY16 Defense Appropriations Act provides $50 million to the Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.

The PRCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY16 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April and July 2016. Pre-application and application deadlines will be available when the Program Announcements are released.

Learn more about this opportunity


NOT-OD-16-031

This notice informs the biomedical and health services research community of planned changes to the PHS Research Performance Progress Report (RPPR) instructions for all annual non-competing (Type 5) NIH & AHRQ awards that support research activities.

These updates to address Rigor and Transparency will take effect for RPPRs due on or after January 25, 2016.

Updates to NIH & AHRQ Research Performance Progress Reports (RPPR)


Lab Size and Strategic Support of Science: Thoughts on Finding the Right Mix

Suppose a funding agency happens to have some extra money and needs to decide how to invest it. Should it invest that extra money in a large, highly productive laboratory, so that laboratory can expand a bit more? Or should it invest that extra money in a small to moderate size laboratory? Given our inability to predict the future with great certainty, which approach represents the smarter investment strategy? Jon Lorsch, the director of the National Institute for General Medical Sciences (NIGMS), has posted an interesting video on just this question.

Continue reading


NOT-PM-16-001

On November 17, the NIH issued the first set of funding opportunities associated with the implementation of the NIH Precision Medicine Initiative ® (PMI) Cohort Program. These included four  funding opportunity announcements for cooperative agreements, and two funding opportunities for Other Transaction awards. Together, the projects these funding opportunities support will build a solid infrastructure for the PMI Cohort Program.

Access all funding opportunities supporting the PMI Cohort Program through the NIH PMI Funding Opportunities page.


NOT-PM-16-001

On November 17, the NIH issued the first set of funding opportunities associated with the implementation of the NIH Precision Medicine Initiative ® (PMI) Cohort Program. These included four  funding opportunity announcements for cooperative agreements, and two funding opportunities for Other Transaction awards. Together, the projects these funding opportunities support will build a solid infrastructure for the PMI Cohort Program.

Access all funding opportunities supporting the PMI Cohort Program through the NIH PMI Funding Opportunities page.


NOT-TR-15-020

Notice of Corrections to PAR-15-173 "Pre-Application for Collaborative Innovation Award, CTSA Program (X02)"

Learn more about this notice


Consideration of Sex as a Biological Variable in NIH-funded Research

Sex and gender play a role in how health and disease processes differ across individuals, and consideration of these factors in research studies informs the development and testing of preventive and therapeutic interventions in both sexes.  This notice focuses on NIH's expectation that scientists will account for the possible role of sex as a biological variable in vertebrate animal and human studies.

Learn more about this notice: NOT-OD-15-102


NIH & AHRQ Announce Upcoming Changes to Policies, Instructions and Forms for 2016 Grant Applications

The planned changes focus on the following areas:

  • Rigor and transparency in research
  • Vertebrate animals
  • Inclusion reporting
  • Data safety monitoring
  • Research training
  • Appendices
  • Font requirements
  • Biosketch clarifications

Some of the new policies require additional data collection and updates to application forms, with phase one implemented for due dates on or after Jan. 25th, 2016 and phase two implemented for due dates on or after May 25th, 2016.

Learn more about the upcoming changes for this notice NOT-OD-16-004


Enhancing Reproducibility through Rigor and Transparency

NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.  The key to the successful application of that knowledge toward health outcomes is scientific rigor in conducting biomedical research.

Learn more about NOT-OD-15-103


NIH Fiscal Policy for Grant Awards - FY2015

Find information about the NIH Fiscal Policy for Grant Awards - FY2015


Reminder: Biosketch Requirements for Due Dates On or After May 25, 2015

Remember, the modified biosketch format is required for applications submitted to NIH for due dates on or after May 25, 2015. Biosketch format pages, instructions, samples and FAQs are available on the Biosketches section of the SF424 (R&R) Forms and Applications page.

Learn more


NIH Increases Salary Cap to $183,300

National Institutes of Health
(NOT-OD-15-049)

Learn more about this increased salary cap


Ruth L. Kirschstein National Research Service Award (NRSA)

(NOT-OD-15-048)
National Institutes of Health

Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2015

External funding opportunities


2016  SITC-Bristol-Myers Squibb Cancer Immunotherapy Translational Fellowship
Society for Immunotherapy of Cancer
Due to the recent research advances, discoveries, and agent approvals, cancer immunotherapy is quickly emerging as one of the four standards of care for cancer patients. To support the development of the next generation of immunotherapy experts, this two-year award (24 months) aims to provide support for an individual who has an MD or combined MD/PhD and a vested interest in furthering the research and translation of cancer immunotherapy.
Funding: Fellowship Period: December 1, 2016 – November 30, 2018
Amount: $200,000 ($100,000 per year for two years)
Key Dates:
Full Application due August 29, 2016


BCRP Breakthrough Award Levels 3 and 4 II
Department of Defense (CDMRP)
W81XWH-16-BCRP- BREAKTHROUGH2_FL34
The intent of the Breakthrough Award is to support promising research that has high potential to
lead to or make breakthroughs in breast cancer. Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.
Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.
Funding: Direct costs budgeted may not exceed $2.5M over 4 years ($4M over 4 years for partnering PI option).
Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. PIs are expected to have experience in successfully leading large-scale projects. 
Funding: Direct costs budgeted may not exceed $10M over 4 years.
Key Dates:
Pre-Application due September 14, 2016
Full Application due December 8, 2016
 
NOTE: A Breakthrough Award Levels 1 and 2 Program Announcement will be released in late August 2016.


RFA-CA-16-014
Cancer Target Discovery and Development Network (U01)
NIH/NCI
This FOA will continue to support the program "Cancer Target Discovery and Development” (CTD^2, pronounced cee-tee-dee-squared).  CTD^2 is focused on efforts that advance cancer research by bridging the knowledge gap between the rapidly increasing volumes of new data generated by comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis.
Funding: Budgets up to $750,000 direct costs per year may be requested, for up to 5 years.
Key Dates:
Full Application due October 3, 2016


PA-16-251
Gene Fusions in Pediatric Sarcomas (R01)
NIH/NCI
The overall goal of this funding opportunity announcement (FOA) is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumor progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel therapeutics.  
Funding: Application budgets are not limited but need to reflect the actual needs of the proposed project. Maximum performance period is 5 years.
Key Dates:
Full Application due October 5, 2016


PAR-16-278
Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention & Control (R21)
The purpose of this FOA is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.
Funding: Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.
Key Dates:
Full Application due October 16, 2016


 NOT-GM-16-111
Notice of Intent to Publish a FOA for the Maximizing Investigators' Research Award for Early Stage Investigators (R35)
The National Institute of General Medical Sciences intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for its Maximizing Investigators' Research Award (MIRA) program initiative.  This FOA will continue pilot testing of the MIRA concept by targeting Early Stage Investigators.  The FOA will be a reissue of RFA-GM-16-003 with the change that New Investigators who are no longer Early Stage Investigators will not be eligible.   Other minor changes are expected to improve the clarity of the announcement.

This Notice is being provided to allow potential applicants sufficient time to develop their applications and to efficiently address the large number of inquiries that have been received regarding NIGMS plans. The Maximizing Investigators' Research Award (MIRA) is a grant to provide support for the program of research in an investigator's laboratory that falls within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding.

Funding: $250,000 direct costs/yr for up to 5 years.
Key Dates: The FOA is expected to be published in the summer 2016 with an expected application due date in the fall 2016.


 Graduate Training in Disparities Research (GTDR)
Susan G. Komen
GTDR Grants are intended to establish and/or to sustain a training program for a minimum of three graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups. Over the past 7 years, Komen has provided funding to outstanding training programs to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes. Komen supports exceptionally creative training programs for students of diverse backgrounds as a means to support innovative breast disparities research.

Funding: Up to $135,000 per year, direct costs only, for up to 3 years.
Key Dates:
Full application due September 20, 2016


Catalyst Research Grants - BMS Supported Projects
AACR (SU2C) with Support from Bristol-Myers Squibb
The SU2C Catalyst Research Grants: BMS Supported Projects takes a structured and prioritized approach to early-phase clinical studies or translational research in order to accelerate the time to get potential new treatment options to patients and bring together all the key players in a collaborative and strategic manner. The project must include nivolumab, ipilimumab, elotuzumab, and/or urelumab alone or in combination with other compounds, biologics, diagnostics, or devices intended as therapeutic interventions, and/or methods for biomarker identification in the following disease areas of interest: lung cancer, head & neck cancers, metastatic melanoma, merkel cell carcinoma, metastatic/invasive bladder cancer, lymphoma (Hodgkin and Non-Hodgkin), and multiple myeloma. If a product is proposed for use that is marketed or is under development by another company, SU2C will act as an honest broker to secure the necessary agreements. Multi-investigator, multi-institutional projects are required. The project must be designed to accelerate the application of therapeutic agents or methods to study in the clinic (i.e., lead to patient enrollment in a study within the timeframe of the grant) and deliver near-term benefit through investigation and data generation by a collaborative SU2C Catalyst BMS Team of expert investigators. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care. An emphasis on early phase, signal-finding clinical trials is encouraged. Clinical trials must be planned so that the final patient is enrolled by the end of the grant term.

Funding: Up to 4 grants will be funded, with a grant amount of $1 Million - $3 Million over 3 year.
Key Dates:
Full application due August 15, 2016


Novel targets for drug development
Grants4Targets - Bayer AG Oncology Grants
Grants are offered for researchers investigating novel drug targets in the fields of Oncology, Gynecology, Cardiology, Hematology and Ophtalmology to promote innovative therapeutic ideas from basic research into novel drugs. We provide financial support to test your hypothesis, start or extend your present research activities.

Oncology Focus on tumor cell proliferation, survival signaling, transcription and chromatin modulation, cell cycle regulation, tumor metabolism, hypoxia, cancer immunotherapy and Antibody Drug Conjugates (ADC) as well as Targeted Thorium Conjugates (TTC).

Target should have shown to be effective/ mechanistically involved in the disease by relevant in vitro or in vivo models. Target is disease-modifying and/or has a proven function in the pathophysiology of a disease.
Funding: There are two types of grants, that will be allocated by Bayer depending on the target, the scientific data provided and the maturity of the proposal.

1) Support grants (€ 5,000 - €10,000) For druggable targets that are at a very early stage of discovery.
2) Focus grants (€ 10,000 - €125,000) For more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug discovery process.

Key Dates:
Target Idea deadline is August 31, 2016


PAR-16-338
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01)
This funding opportunity encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Funding: Application budgets should reflect the actual needs of the proposed project. The maximum project period is 5 years.
Key Dates:
Full application due October 5, 2016


Graduate Training in Disparities Reasearch (GTDR)
Susan G. Komen
GTDR Grants are intended to establish and/or to sustain a training program for a minimum of three graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups. GTDR Grants will only be a one step process for FY17 and will not require a Letter of Intent. The Request for Applications (RFA) will be released later this summer.
Funding: Up to $135,000 per year, direct costs only, for up to 3 years
Key Dates:
Full application due September 2016.


Clinical Consortium Research Site Award
Department of Defense Prostate Cancer Research Program
The Clinical Consortium Research Site Award provides the support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute Phase II or Phase II-linked Phase I (Phase I/II) prostate cancer clinical trials. These trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer, especially as pertaining to the FY16 PCRP overarching challenges. In accordance with PCRP goals, the conduct of Phase I/II trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer is particularly encouraged.

Funding: $200,000
Key Dates:
Pre-application deadline: September 15, 2016, 5 p.m. ET
Full application: October 11, 2016, 11:59 p.m. ET


PAR-16-338
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01)
This funding opportunity encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Funding: Application budgets should reflect the actual needs of the proposed project. The maximum project period is 5 years.
Key Dates:
Full application due October 5, 2016


PA-16-294
NIH Support for Conferences and Scientific Meetings (Parent R13)
The purpose of the NIH Research Conference Grant (R13) is to support high quality scientific conferences that are relevant to the NIH's mission and to the public health. A conference is defined as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face or via the internet, where individuals assemble (or meet virtually) for the primary purpose to exchange technical information and views or explore or clarify a defined subject, problem, or area of knowledge, whether or not a published report results from such meeting. The NIH recognizes the value to members of the research community and all other interested parties in supporting such forums. Support of conferences is contingent on the fiscal and programmatic interests and priorities of the individual NIH Institutes and Centers (ICs). Therefore, a conference grant application is required to contain a permission-to-submit letter from any one of the participating ICs’ conference grant contact person (see Contacts List). Applicants are urged to initiate contact well in advance of the chosen application due date and no later than 6 weeks before that date. Please note that agreement to accept an application does not guarantee funding. In general, NIH will not issue a conference grant award unless the Federal award date can precede the conference start date.

Key Dates:
Full application due August 12, 2016


PA-16-307
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)
NIH/NCI
The overall goal of the NIH Ruth L. Kirschstein National Research Service Award (NRSA) program is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's biomedical, behavioral, and clinical research needs. NRSA fellowships support the training of pre-and postdoctoral scientists, dual-degree investigators, and senior researchers.
Funding: Award budgets are composed of stipends, tuition and fees, and institutional allowance.
Key Dates:
Full application due August 8, 2016.


Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment

PAR-16-212 (R01) and PAR-16-213 (R21)
NIH/NCI
This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as “chemobrain.” A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

Funding:

(R01) - Maximum project period is 5 years. Application budgets should reflect the actual needs of the proposed project.
(R21) - The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Key Dates:
Full application due date for both the (R01) and (R21) is October 13, 2016.


Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions

PAR-16-202 (R01) and PAR-16-201 (R21)
NIH/NCI
The purpose of this Funding Opportunity Announcement (FOA) is to provide support for innovative and promising intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations. Specifically, this FOA is intended to stimulate research efforts aimed at the development of smoking cessation interventions that: 1) are targeted to socioeconomically disadvantaged populations, and 2) could be made scalable for broad population impact. Applicants may propose projects that develop and test novel cessation interventions with the potential to be scaled up, as well as projects that focus on enhancing the effectiveness, quality, accessibility, utilization, and cost-effectiveness of currently scaled smoking cessation interventions. This FOA provides funding for up to 2 years for protocol development and early phase, pilot, or exploratory projects.

Funding:

(R01) - Maximum project period is 5 years. Application budgets should reflect the actual needs of the proposed project.
(R21) - The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Key Dates:
Full application due date for both the (R01) and (R21) is October 11, 2016.


Detection of Pathogen-Induced Cancer (DPIC) (R01)

PAR-13-190
This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is to encourage research projects which focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer.

Funding:

Application budgets are not limited, but need to reflect actual needs of the proposed project.

Key Dates:

Full application due July 10, 2016


Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)

(NOT-OD-15-044)
(PAR-15-075)
National Cancer Institute

Funding:

Standard R01 limits apply

Application Receipt Date(s):

Standard dates apply, by 5:00 PM local time of applicant organization.


NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

(PAR-15-064)
National Cancer Institute

Funding:

$100,000/yr towards salary; $30,000/yr for other expenses

Application Receipt Date(s):

Multiple dates, see announcement.


NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08)

(PAR-15-060)
National Cancer Institute

Funding:

$100,000/yr towards salary; $30,000/yr for other expenses

Application Receipt Date(s):

Multiple dates, see announcement.


NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23)

(PAR-15-062)
National Cancer Institute

Application Receipt Date(s):

Multiple dates, see announcement.

Funding:

$100,000/yr towards salary; $30,000/yr for other expenses


National Cancer Institute Program Project Applications (P01)

(PAR-15-023)
National Cancer Institute

Application Receipt Date(s):

Multiple dates, see announcement.

Funding:

Varies. 


Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015 and 2016 (P50)

(PAR-14-353)
National Cancer Institute

Application Receipt Date(s):

May 19, 2016; September 22, 2016

Funding:

$2,300,000 total costs/year 


Advancing Interventions to Improve Medication Adherence

PA-14-334 – R01 and PA-14-335 – R21

National Cancer Institute

Application Receipt Date(s):

Multiple dates, see announcement.

Funding:

Standard R01 & R21 limit


Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01)

(PAR-14-242)
National Cancer Institute

Application Receipt Date(s):  

See announcement for dates.

Funding:

Standard R01 limits apply 


Interventions for Health Promotion and Disease Prevention in Native American Populations (R01)

(PAR-14-260)
National Cancer Institute

Application Receipt Date(s):

May 12, 2016, See announcement for additional dates.

Funding:

Standard R01 limits apply.


Genomic Resource Grants for Community Resource Projects (U41)

(PAR-14-191)
National Cancer Institute

Funding:

5 years of funding.  Application budgets are not limited, but should reflect the needs of the proposed project.

Application Receipt Date(s):

May 25, 2016; September 25, 2016; January 25, 2017


Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01)

(PA-14-114)
National Cancer Institute

Funding:

Standard R01 limits apply.

Application Receipt Date(s):

Multiple dates, see announcement.


Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)

(PAR-14-013)
National Cancer Institute

Funding:

Standard R21 limits apply

Deadline:

See announcement for dates.  


Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01)

(PAR-14-116)
National Cancer Institute

Funding:

$500,000/yr for 5 years

Application Receipt Date(s):

Multiple dates, see announcement 


Modeling Social Behavior (R01)

(PAR-13-374)
National Cancer Institute

Funding:

Standard R01 limits apply

Deadline:

Multiple dates, see announcement.


Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01)

(PAR-13-375)
National Cancer Institute

Funding:

Standard R01 limits apply.

Deadline:

March 22, 2016


Pancreatic Cancer Action Network Research Grants Program

Sponsor:

Pancreatic Cancer Action Network and American Association for Cancer Research

Funding is available for postdoctoral/clinical research fellows as well as for junior and senior independent researchers. The proposed research must be directly relevant to pancreatic cancer. More information about the grants program, including eligibility criteria and application due dates and procedures, is available at http://www.pancan.org/2014grants.

Funding:

See announcement

Deadlines:

Multiple; see announcement


 

Research to Characterize and Reduce Stigma to Improve Health

R01 (PA-13-248), R03 (PA-13-247) and R21 (PA-13-246)

National Cancer Institute

Funding:

Standard limits apply.

Application Receipt Date(s):

Multiple dates, see announcement.  Standard cycle dates.


Prostate Cancer Research Program (PCRP)

Sponsor:

Department of Defense

Funding:

See announcements

Deadlines:

Various; see announcements


Innovative Research Methods: Prevention and Management of Symptoms in Chronic Illness

R01 (PA-13-165), R15 (PA-13-166) and R21 (PA-13-167)

National Cancer Institute

Funding:

Standard limits apply. See announcements for additional information

Application Receipt Date(s):

Multiple dates, see announcement.


Bioengineering Research Grants (BRG) (R01)

(PAR-13-137)
National Cancer Institute

Funding:

Standard R01 limits apply.

Application Deadline: 

Multiple receipt dates, see announcement.


Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)

(PAR-13-169)
National Cancer Institute

Funding:

standard R01 limits apply

Application Receipt Date(s):

Multiple dates, see announcement.

NOT-GM-16-111

Notice of Intent to Publish a FOA for the Maximizing Investigators' Research Award for Early Stage Investigators (R35)

The National Institute of General Medical Sciences intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for its Maximizing Investigators' Research Award (MIRA) program initiative.  This FOA will continue pilot testing of the MIRA concept by targeting Early Stage Investigators.  The FOA will be a reissue of RFA-GM-16-003 with the change that New Investigators who are no longer Early Stage Investigators will not be eligible.   Other minor changes are expected to improve the clarity of the announcement.

This Notice is being provided to allow potential applicants sufficient time to develop their applications and to efficiently address the large number of inquiries that have been received regarding NIGMS plans. The Maximizing Investigators' Research Award (MIRA) is a grant to provide support for the program of research in an investigator's laboratory that falls within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding.

Funding: $250,000 direct costs/yr for up to 5 years.

Key Dates: The FOA is expected to be published in the summer 2016 with an expected application due date in the fall 2016.

 

Graduate Training in Disparities Research (GTDR)

Susan G. Komen

GTDR Grants are intended to establish and/or to sustain a training program for a minimum of three graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups. Over the past 7 years, Komen has provided funding to outstanding training programs to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes. Komen supports exceptionally creative training programs for students of diverse backgrounds as a means to support innovative breast disparities research.

Funding: Up to $135,000 per year, direct costs only, for up to 3 years.

Key Dates:

Full application due September 20, 2016

 

Catalyst Research Grants - BMS Supported Projects

AACR (SU2C) with Support from Bristol-Myers Squibb

​The SU2C Catalyst Research Grants: BMS Supported Projects takes a structured and prioritized approach to early-phase clinical studies or translational research in order to accelerate the time to get potential new treatment options to patients and bring together all the key players in a collaborative and strategic manner. The project must include nivolumab, ipilimumab, elotuzumab, and/or urelumab alone or in combination with other compounds, biologics, diagnostics, or devices intended as therapeutic interventions, and/or methods for biomarker identification in the following disease areas of interest: lung cancer, head & neck cancers, metastatic melanoma, merkel cell carcinoma, metastatic/invasive bladder cancer, lymphoma (Hodgkin and Non-Hodgkin), and multiple myeloma. If a product is proposed for use that is marketed or is under development by another company, SU2C will act as an honest broker to secure the necessary agreements. Multi-investigator, multi-institutional projects are required. The project must be designed to accelerate the application of therapeutic agents or methods to study in the clinic (i.e., lead to patient enrollment in a study within the timeframe of the grant) and deliver near-term benefit through investigation and data generation by a collaborative SU2C Catalyst BMS Team of expert investigators. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care. An emphasis on early phase, signal-finding clinical trials is encouraged. Clinical trials must be planned so that the final patient is enrolled by the end of the grant term.

Funding: Up to 4 grants will be funded, with a grant amount of $1 Million - $3 Million over 3 year.

Key Dates:

Full application due August 15, 2016

 

Novel targets for drug development

Grants4Targets - Bayer AG Oncology Grants

Grants are offered for researchers investigating novel drug targets in the fields of Oncology, Gynecology, Cardiology, Hematology and Ophtalmology to promote innovative therapeutic ideas from basic research into novel drugs. We provide financial support to test your hypothesis, start or extend your present research activities.

Oncology Focus on tumor cell proliferation, survival signaling, transcription and chromatin modulation, cell cycle regulation, tumor metabolism, hypoxia, cancer immunotherapy and Antibody Drug Conjugates (ADC) as well as Targeted Thorium Conjugates (TTC).

Target should have shown to be effective/ mechanistically involved in the disease by relevant in vitro or in vivo models.

Target is disease-modifying and/or has a proven function in the pathophysiology of a disease.

Funding: There are two types of grants, that will be allocated by Bayer depending on the target, the scientific data provided and the maturity of the proposal.

1) Support grants (€ 5,000 - €10,000) For druggable targets that are at a very early stage of discovery.

2) Focus grants (€ 10,000 - €125,000) For more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug discovery process.

Key Dates:

Target Idea deadline is August 31, 2016

 

MCC and UMN funding opportunities

Masonic Cancer Center Internal Funding Opportunities

  • Pre-R01 Pilot Grants
  • American Cancer Society’s Institutional Research Grant University of Minnesota (application period closed) 

Other University of Minnesota Funding Opportunities

Funding resources

Federal agencies funding cancer-related research

Search funding opportunities; sign up to receive the NIH Guide weekly via e-mail.

Search for funding sources by keyword; sign up for e-mail notification of funding opportunities. (Note: NIH listings are under DHHS, the Department of Health and Human Services.)

Non-federal agencies funding cancer-related research

Research funding directories

CFDA is a database of all federal programs available to state and local governments; federally recognized Indian tribal governments; territories (and possessions) of the United States; domestic public, quasi-public, and private profit and nonprofit organizations and institutions; specialized groups; and individuals.

This funding opportunity search engine provides the world's most comprehensive funding resource, with more than 24,000 records representing nearly 400,000 opportunities ranging from local non-profit funding to federally funded grants.

This is a sortable database of current funding opportunities pulled from various databases. It boasts a user-friendly interface and a comprehensive listing. While the listing is not as comprehensive as other databases in this list, opportunities may be easier to find in this abbreviated format.

(requires x.500 login)

The premier grantseeking database on the Web, developed by the Foundation Center, a national nonprofit service organization founded over 50 years ago to open up U.S. foundations to public view.

A fee-based service, to which the University of Minnesota is a current subscriber. It currently contains over 9,000 active federal and private funding opportunities in the sciences, social sciences, arts, and humanities. In addition to funding opportunities for faculty, the IRIS Database also contains fellowships and scholarships for grad students and undergrads. Users can search IRIS by sponsor, deadline date, keyword, and other criteria. Most IRIS records contain live links to sponsor Web sites, electronic forms, or Electronic Research Administration (eRA) portals. The IRIS Database is updated daily.

InfoEd's SPIN is the most widely used funding opportunity database in the world. By aggregating sponsor information in one system, SPIN dramatically cuts search times and substantially increases the likelihood of positive results. Program information is presented in a standard format that allows investigators to readily compare opportunities. This search engine is great for post-doctoral associates looking for funding opportunities.